Insider Trading Alert - GWRE, AVB And OPK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, May 2, 2014, 147 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $416.76 to $333,500,000.00.

Highlighted Stocks Traded by Insiders:

Guidewire Software (GWRE) - FREE Research Report

Conway Craig, who is Director at Guidewire Software, sold 12,000 shares at $38.68 on May 2, 2014. Following this transaction, the Director owned 143,472 shares meaning that the stake was reduced by 7.72% with the 12,000-share transaction.

The shares most recently traded at $38.52, down $0.16, or 0.43% since the insider transaction. Historical insider transactions for Guidewire Software go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 170,278
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 429,131

The average volume for Guidewire Software has been 592,800 shares per day over the past 30 days. Guidewire Software has a market cap of $2.6 billion and is part of the technology sector and computer software & services industry. Shares are down 20.54% year-to-date as of the close of trading on Friday.

Guidewire Software, Inc. provides system software to the property and casualty (P&C) insurance industry primarily in the United States, Canada, Australia, the United Kingdom, and internationally. Currently, there are 4 analysts who rate Guidewire Software a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GWRE - FREE

TheStreet Quant Ratings rates Guidewire Software as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Guidewire Software Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AvalonBay Communities (AVB) - FREE Research Report

O'Shea Kevin P., who is Executive Vice President at AvalonBay Communities, sold 747 shares at $136.44 on May 2, 2014. Following this transaction, the Executive Vice President owned 7,379 shares meaning that the stake was reduced by 9.19% with the 747-share transaction.

The shares most recently traded at $137.72, up $1.28, or 0.93% since the insider transaction. Historical insider transactions for AvalonBay Communities go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 9,383
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 13,058
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 13,058

The average volume for AvalonBay Communities has been 873,200 shares per day over the past 30 days. AvalonBay Communities has a market cap of $17.8 billion and is part of the financial sector and real estate industry. Shares are up 15.94% year-to-date as of the close of trading on Friday.

AvalonBay Communities, Inc. engages in the development, redevelopment, acquisition, ownership, and operation of multifamily communities in the United States. The stock currently has a dividend yield of 3.57%. The company has a P/E ratio of 282.8. Currently, there are 8 analysts who rate AvalonBay Communities a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AVB - FREE

TheStreet Quant Ratings rates AvalonBay Communities as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full AvalonBay Communities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al, who is CEO & Chairman at Opko Health, bought 20,000 shares at $8.36 on May 2, 2014. Following this transaction, the CEO & Chairman owned 140.6 million shares meaning that the stake was reduced by 0.01% with the 20,000-share transaction.

The shares most recently traded at $8.29, down $0.07, or 0.83% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 40,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 2.9 million shares per day over the past 30 days. Opko Health has a market cap of $3.4 billion and is part of the health care sector and health services industry. Shares are down 2.25% year-to-date as of the close of trading on Friday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently, there are 4 analysts who rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength